Compare MPLT & SCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPLT | SCL |
|---|---|---|
| Founded | 2018 | 1932 |
| Country | United States | United States |
| Employees | 133 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | N/A | 1994 |
| Metric | MPLT | SCL |
|---|---|---|
| Price | $27.75 | $54.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $32.67 | ★ $75.00 |
| AVG Volume (30 Days) | ★ 266.3K | 95.5K |
| Earning Date | 05-28-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 3.23% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,803,737,000.00 |
| Revenue This Year | N/A | $6.60 |
| Revenue Next Year | N/A | $5.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.24 | $41.82 |
| 52 Week High | $33.28 | $68.00 |
| Indicator | MPLT | SCL |
|---|---|---|
| Relative Strength Index (RSI) | 49.78 | 61.74 |
| Support Level | $26.07 | $48.88 |
| Resistance Level | $31.69 | $54.46 |
| Average True Range (ATR) | 2.37 | 1.33 |
| MACD | -0.10 | 0.12 |
| Stochastic Oscillator | 53.11 | 86.10 |
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
Stepan Co manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on product type. The surfactants segment, which generates the majority of revenue, sells cleaning agents used in detergents, shampoos, body wash, fabric softeners, toothpastes, and other personal-care products. The polymers segment sells polyurethane used to manufacture rigid foam for thermal insulation, as well as phthalic anhydride used to make plastic components for the construction, automotive, and boating industries. The specialty products segment sells chemicals used in food and flavoring. The majority of Stepan's revenue comes from the United States, followed by France, Poland, the United Kingdom, Brazil, Mexico, and other countries.